Melbourne, Jan 17, 2008 (ABN Newswire) - The Directors are pleased to announce that Solagran Limited (ASX: SLA) has engaged the Bank of New York to establish a level one American Depository Receipt (ADR) Program.
This ADR Program will make Solagran securities more accessible to the US institutional and retail investors, without incurring the compliance costs of a full exchange listing. It will help facilitate the purchase of Solagran securities by US Investors.
The Directors believe the ADR Program is an important step towards the eventual establishment of a production facility in North America and licensing agreements for product distribution in the region.
About SOLAGRAN LIMITED
Solagran is a biotechnology company with a portfolio of higly effective, low side effect, natural pharmaceuticals that it obtains from gree tree foliage. Its patented technology enables the extraction of the live elements of trees in a way that both preserves and amplifies their biological activity.